keyword
MENU ▼
Read by QxMD icon Read
search

Her2 positive, hormone positive

keyword
https://www.readbyqxmd.com/read/28534351/the-short-term-safety-of-adjuvant-paclitaxel-plus-trastuzumab-a-single-centre-experience
#1
Ozturk Ates, Veli Sunar, Alma Aslan, Fatih Karatas, Suleyman Sahin, Kadri Altundag
PURPOSE: HER2-amplified breast cancer (BC) has a poor prognosis. The combination of trastuzumab with chemotherapy in the adjuvant setting decreases recurrence and improves overall survival in HER2-positive BC. However, the role of adjuvant treatment in patients with HER2-amplified small BC without lymph node involvement is still under debate. The purpose of this study was to investigate the safety of adjuvant paclitaxel and trastuzumab (APT) in this group of patients. METHODS: A total of 87 operated early BC patients without lymph node involvement (N0) were treated with APT for 12 weeks followed by trastuzumab alone for a total of 9 months...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28533475/first-line-palliative-her2-targeted-therapy-in-her2-positive-metastatic-breast-cancer-is-less-effective-after-previous-adjuvant-trastuzumab-based-therapy
#2
Hánah N Rier, Mark-David Levin, Joost van Rosmalen, Monique M E M Bos, Jan C Drooger, Paul de Jong, Johanneke E A Portielje, Elisabeth M P Elsten, Albert-Jan Ten Tije, Stefan Sleijfer, Agnes Jager
BACKGROUND: Survival of patients with human epidermal growth receptor 2 (HER2)-positive metastatic breast cancer (MBC) has improved dramatically since trastuzumab has become available, although the disease eventually progresses in most patients. This study investigates the outcome (overall survival [OS] and time to next treatment [TNT]) in MBC patients pretreated with trastuzumab in the adjuvant setting (TP-group) compared with trastuzumab-naïve patients (TN-group) in order to investigate the possibility of trastuzumab resistance...
May 22, 2017: Oncologist
https://www.readbyqxmd.com/read/28533223/monarch-1-a-phase-2-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single-agent-in-patients-with-refractory-hr-her2-metastatic-breast-cancer
#3
Maura N Dickler, Sara Tolaney, Hope S Rugo, Javier Cortés, Veronique Dieras, Debra A Patt, Hans Wildiers, Clifford A Hudis, Joyce A O'Shaughnessy, Esther Zamora, Denise Yardley, Martin Frenzel, Andrew G Koustenis, José Baselga
<br />The phase 2 MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 and CDK6, in women with refractory hormone receptor positive (HR+), HER2- metastatic breast cancer (MBC). <br /><br />Experimental Design: <br />MONARCH 1 was a phase 2 single arm open-label study. Women with HR+/HER2- MBC who had progressed on or after prior endocrine therapy and had 1 or 2 chemotherapy regimens in the metastatic setting were eligible...
May 22, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28527420/factors-predictive-of-locoregional-recurrence-following-neoadjuvant-chemotherapy-in-patients-with-large-operable-or-locally-advanced-breast-cancer-an-analysis-of-the-eortc-10994-big-1-00-study
#4
Pauline Gillon, Nathan Touati, Christel Breton-Callu, Leen Slaets, David Cameron, Hervé Bonnefoi
PURPOSE: Identification of clinicopathological factors predicting for a locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC) could help to decide on the optimal locoregional radiotherapy. The objective of this trial is to identify those factors in the context of a phase III trial (European Organisation for Research and Treatment of Cancer 10994). METHODS: Patients received NAC followed by surgery with or without radiotherapy. Radiotherapy was administered according to pre-specified guidelines...
May 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28523293/-triple-positive-breast-cancer-a-novel-category
#5
George Iancu, DănuŢ Vasile, Raluca Claudia Iancu, Dragoş Virgil DaviŢoiu
Breast cancer (BC) biology is of outmost importance for its therapeutic management and for establishing patients' outcome. Breast cancer has been divided in subtypes depending on the presence of hormone receptors (HRs) for estrogen and progesterone and human epidermal growth factor receptor 2 (HER2) gene amplification. Recently, a distinct subcategory has been analyzed from the group of HER2-enriched BC with positive HR, namely HER2 positive with high levels of hormone receptor expression, suggestively named "triple positive" breast cancer...
2017: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/28521821/intratumoral-and-peritumoral-radiomics-for-the-pretreatment-prediction-of-pathological-complete-response-to-neoadjuvant-chemotherapy-based-on-breast-dce-mri
#6
Nathaniel M Braman, Maryam Etesami, Prateek Prasanna, Christina Dubchuk, Hannah Gilmore, Pallavi Tiwari, Donna Pletcha, Anant Madabhushi
BACKGROUND: In this study, we evaluated the ability of radiomic textural analysis of intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). METHODS: A total of 117 patients who had received NAC were retrospectively analyzed. Within the intratumoral and peritumoral regions of T1-weighted contrast-enhanced MRI scans, a total of 99 radiomic textural features were computed at multiple phases...
May 18, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28498399/dual-inhibition-of-igf1r-and-er-enhances-response-to-trastuzumab-in-her2-positive-breast-cancer-cells
#7
Martina S J McDermott, Alexandra Canonici, Laura Ivers, Brigid C Browne, Stephen F Madden, Neil A O'Brien, John Crown, Norma O'Donovan
Although HER2 targeted therapies have improved prognosis for HER2 positive breast cancer, HER2 positive cancers which co-express ER have poorer response rates to standard HER2 targeted therapies, combined with chemotherapy, than HER2 positive/ER negative breast cancer. Administration of hormone therapy concurrently with chemotherapy and HER2 targeted therapy is generally not recommended. Using publically available gene expression datasets we found that high expression of IGF1R is associated with shorter disease-free survival in patients whose tumors are ER positive and HER2 positive...
April 26, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28488183/palbociclib-a-review-in-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer
#8
REVIEW
Esther S Kim, Lesley J Scott
Oral palbociclib (Ibrance®) is a first-in-class, highly selective inhibitor of cyclin-dependent kinases 4 and 6 (i.e. a CDK4/6 inhibitor). It is indicated for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, and in combination with fulvestrant (with or without a luteinizing hormone-releasing hormone agonist) in those previously treated with endocrine therapy. In clinical trials, palbociclib in combination with letrozole as initial endocrine-based therapy in postmenopausal women (PALOMA-1 and PALOMA-2), or in combination with fulvestrant in pre-, peri-, or postmenopausal women with disease progression after endocrine therapy (PALOMA-3), significantly prolonged progression-free survival (PFS) and improved clinical benefit response (CBR) rates...
May 9, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28484080/neoadjuvant-chemotherapy-increases-rates-of-breast-conserving-surgery-in-early-operable-breast-cancer
#9
V Cm Man, P Sy Cheung
INTRODUCTION: Neoadjuvant chemotherapy is commonly used in stage III breast cancer for disease down-staging. Its use has now been extended to early breast cancer to increase the rate of breast-conserving surgery. This study aimed to evaluate the effectiveness of neoadjuvant chemotherapy in early operable cancers. METHODS: A retrospective study was carried out at the Hong Kong Sanatorium & Hospital of 102 patients with stage I to III primary breast cancer. All patients who underwent neoadjuvant chemotherapy followed by definitive breast surgery between January 2004 and July 2013 were included...
May 9, 2017: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/28476740/initiation-of-trastuzumab-by-women-younger-than-64-years-for-adjuvant-treatment-of-stage-i-iii-breast-cancer
#10
Huei-Ting Tsai, Claudine Isaacs, Filipa C Lynce, Suzanne C O'Neill, Chunfu Liu, Marc D Schwartz, Nandini Selvam, Yingjun Zhou, Arnold L Potosky
Purpose: Studies have reported disparities by age and race in the initiation of adjuvant trastuzumab for the initial treatment of older women with early-stage breast cancer, but less is known about its initiation in younger patients. Therefore, we assessed temporal trends and clinical and demographic factors associated with trastuzumab initiation in a large, population-based cohort of patients aged <64 years in 5 states. Methods: Using a cancer registry and claims-linked data set of 13,398 women with incident invasive breast cancer from 2006 to 2011, we identified 934 patients aged <64 years with HER2-positive stage I-III breast cancer...
May 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28475932/therapeutic-escalation-de-escalation-data-from-15-508-early-breast-cancer-treated-with-upfront-surgery-and-sentinel-lymph-node-biopsy-slnb
#11
Gilles Houvenaeghel, Eric Lambaudie, Monique Cohen, Jean-Marc Classe, Fabien Reyal, Jean-Rémy Garbay, Sylvia Giard, Nicolas Chopin, Alejandra Martinez, Roman Rouzier, Emile Daraï, Pierre Emmanuel Colombo, Charles Coutant, Pierre Gimbergues, Pierre Azuar, Richard Villet, Christine Tunon de Lara, Emmanuel Barranger, Laura Sabiani, Anthony Goncalves
INTRODUCTION: The aim of this study was to examine changes in therapeutic practices for early breast cancer T0-2 N0 managed by upfront surgery and SLNB. POPULATION: Between 1999 and 2012, 15.508 patients were treated. Four periods were determined: 1999-2003, 2004-2006, 2007-2009 and > 2009. Five tumor subtypes were defined according to hormonal receptors (HR) and Her2: Luminal A (HR + Her2- Grade 1-2), Her2 (Her2+ HR-), Triple-negative (HR- Her2-), Luminal B Her2- (HR + Her2- Grade 3), Luminal B Her2+ (HR + HER2+)...
May 2, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28472761/outcomes-of-patients-with-inflammatory-breast-cancer-by-hormone-receptor-and-her2-defined-molecular-subtypes-a-population-based-study-from-the-seer-program
#12
Juanjuan Li, Yue Xia, Qi Wu, Shan Zhu, Chuang Chen, Wen Yang, Wen Wei, Shengrong Sun
BACKGROUND: The aim of this study was to evaluate the outcomes of patients with inflammatory breast cancer (IBC), with emphasis on the role of molecular subtypes and radiotherapy. METHODS: A retrospective cohort study to investigate overall survival (OS) and breast cancer-specific mortality (BCSM) in patients with IBC was conducted using data obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010-2013. Cox multivariate regression was used to calculate the adjusted Hazard Ratios (aHR)...
April 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28460643/regular-and-low-dose-aspirin-other-non-steroidal-anti-inflammatory-medications-and-prospective-risk-of-her2-defined-breast-cancer-the-california-teachers-study
#13
Christina A Clarke, Alison J Canchola, Lisa M Moy, Susan L Neuhausen, Nadia T Chung, James V Lacey, Leslie Bernstein
BACKGROUND: Regular users of aspirin may have reduced risk of breast cancer. Few studies have addressed whether risk reduction pertains to specific breast cancer subtypes defined jointly by hormone receptor (estrogen and progesterone receptor) and human epidermal growth factor receptor 2 (HER2) expression. This study assessed the prospective risk of breast cancer (overall and by subtype) according to use of aspirin and other non-steroidal anti-inflammatory medications (NSAIDs) in a cohort of female public school professionals in California...
May 1, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28459941/german-adjuvant-intergroup-node-positive-study-gain-a-phase-iii-trial-comparing-two-dose-dense-regimens-iddepc-vs-ddec-pwx-in-high-risk-early-breast-cancer-patients
#14
V Moebus, G von Minckwitz, C Jackisch, H-J Lück, A Schneeweiss, H Tesch, D Elling, N Harbeck, B Conrad, T Fehm, J Huober, V Müller, I Bauerfeind, A du Bois, S Loibl, V Nekljudova, M Untch, C Thomssen
Background: Dose-dense (dd) regimens are one of the preferred options for the adjuvant treatment of breast cancer patients with intermediate to high risk. The GAIN trial aimed at optimizing intense dose-dense (idd) strategies by evaluating drug combinations and the addition of capecitabine. Patients and Methods: Women (aged 18 and biologically <65 years) with histologically involved axillary lymph nodes were randomly assigned to receive three courses each of epirubicin (E) 150mg/m 2 , paclitaxel (P) 225mg/m 2 and cyclophosphamide (C) 2500mg/m 2 (reduced to 2000mg/m 2 after recruitment of 1200 patients) q2w intravenously (i...
April 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28454109/anthropometric-clinical-and-molecular-determinants-of-treatment-outcomes-in-postmenopausal-hormone-receptor-positive-metastatic-breast-cancer-patients-treated-with-fulvestrant-results-from-a-real-word-setting
#15
Laura Pizzuti, Clara Natoli, Teresa Gamucci, Mariella Mauri, Domenico Sergi, Luigi Di Lauro, Giancarlo Paoletti, Enzo Ruggeri, Laura Iezzi, Isabella Sperduti, Lucia Mentuccia, Agnese Fabbri, Marcello Maugeri-Saccà, Luca Moscetti, Maddalena Barba, Patrizia Vici
To characterize determinants of treatment outcome in a real world population of 161 post-menopausal hormone receptor-positive metastatic breast cancer patients treated with fulvestrant. Descriptive statistics for demographics, anthropometrics, clinical and molecular characteristic were compared across subgroups of sensitivity/resistance to prior endocrine therapy and tested in uni/multivariate models. Clinical benefit was more common in sensitive patients with higher estrogen receptor expression and when fulvestrant was given in first line (p=0...
April 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28451590/molecular-signaling-of-progesterone-growth-hormone-wnt-and-her-in-mammary-glands-of-dogs-rodents-and-humans-new-treatment-target-identification
#16
REVIEW
Elpetra P M Timmermans-Sprang, Ana Gracanin, Jan A Mol
Mammary tumors are the most common form of neoplasia in the bitch. Female dogs are protected when they are spayed before the first estrus cycle, but this effect readily disappears and is already absent when dogs are spayed after the second heat. As the ovaries are removed during spaying, ovarian steroids are assumed to play an essential role in tumor development. The sensitivity toward tumor development is already present during early life, which may be caused by early mutations in stem cells during the first estrus cycles...
2017: Frontiers in Veterinary Science
https://www.readbyqxmd.com/read/28450990/-anatomopathological-profile-of-breast-cancer-in-cape-bon-tunisia
#17
Ghada Sahraoui, Fatma Khanchel, Emna Chelbi
Breast cancer is the most common cancer among tunisian women and worldwide. In Cape Bon, Tunisia, the anatomopathological features of this cancer have not been established in previously published studies. Knowledge about these features is needed for the cultural adaptation of prevention and health care systems in the region. The aim of our study was to determine the pathological profile of breast cancers in the only public health anatomic pathology regional laboratory. We conducted a retrospective descriptive study of 116 patients who were diagnosed with breast cancers in our laboratory over a 5-year period, from July 2010 to July 2015...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28442763/impact-of-hormone-receptor-status-and-distant-recurrence-free-interval-on-survival-benefits-from-trastuzumab-in-her2-positive-metastatic-breast-cancer
#18
Hai-Yuan Yang, Ding Ma, Yi-Rong Liu, Xin Hu, Jian Zhang, Zhong-Hua Wang, Gen-Hong Di, Xi-Chun Hu, Zhi-Ming Shao
We sought to investigate the impact of hormone receptor (HR) status and distant recurrence-free interval (DRFI) on the degree of overall survival (OS) benefit from palliative trastuzumab-containing treatment in HER2-positive metastatic breast cancer (MBC). Here, we retrospectively identified 588 eligible HER2-positive patients with postoperative distant recurrence. DRFI of HR+HER2+ MBC patients (median: 30.7 months, IQR: 18.5-45.9, P < 0.001) was significant longer compared with HR-HER2+ patients. Patients were categorized into four subgroups based on HR status and palliative trastuzumab (trast+) received...
April 25, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28441617/the-magic-survey-in-hormone-receptor-positive-hr-her2-negative-her2-breast-cancer-when-might-multigene-assays-be-of-value
#19
Matti Aapro, Michelino De Laurentiis, Dan Rea, Juan Enrique Bargallo Rocha, Roberto Elizalde, László Landherr, Barbro Linderholm, Eleftherios Mamounas, Christos Markopoulos, Patrick Neven, Alexander Petrovsky, Roman Rouzier, Vincent Smit, Christer Svedman, Daniel Schneider, Christoph Thomssen, Miguel Martin
BACKGROUND: A modest proportion of patients with early stage hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer benefit from adjuvant chemotherapy. Traditionally, treatment recommendations are based on clinical/pathologic criteria that are not predictive of chemotherapy benefit. Multigene assays provide prognostic and predictive information that can help to make more informed treatment decisions. The MAGIC survey evaluated international differences in treatment recommendations, how traditional parameters are used for making treatment choices, and for which patients treating physicians feel most uncertain about their decisions...
June 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28432515/mri-predicts-pathologic-complete-response-in-her2-positive-breast-cancer-after-neoadjuvant-chemotherapy
#20
Mette S van Ramshorst, Claudette E Loo, Emilie J Groen, Gonneke H Winter-Warnars, Jelle Wesseling, Frederieke van Duijnhoven, Marie-Jeanne T Vrancken Peeters, Gabe S Sonke
BACKGROUND: Neoadjuvant treatment of HER2-positive breast cancer frequently leads to a pathologic complete response (pCR), which is associated with favourable long-term outcome. Treatment regimens typically consist of 6-9 cycles of trastuzumab-based chemotherapy, although many patients achieve early radiologic complete response (rCR). If rCR accurately predicts pCR, the number of chemotherapy cycles can possibly be reduced. METHODS: We performed a diagnostic accuracy study to determine the association between rCR and pCR in patients with stage II-III HER2-positive breast cancer treated with neoadjuvant trastuzumab-based chemotherapy at the Netherlands Cancer Institute...
April 21, 2017: Breast Cancer Research and Treatment
keyword
keyword
21972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"